Pages that link to "Q24564715"
Jump to navigation
Jump to search
The following pages link to Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial (Q24564715):
Displaying 50 items.
- Ponesimod, a selective S1P1 receptor modulator: a potential treatment for multiple sclerosis and other immune-mediated diseases (Q26771821) (← links)
- Sphingosine 1-phosphate receptor modulators in multiple sclerosis (Q26799440) (← links)
- Therapeutic interference with leukocyte recirculation in multiple sclerosis. (Q30884219) (← links)
- Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial (Q34433768) (← links)
- Mass balance, pharmacokinetics and metabolism of the selective S1P1 receptor modulator ponesimod in humans (Q34436863) (← links)
- Effect of ponesimod, a selective S1P1 receptor modulator, on the QT interval in healthy individuals (Q34442025) (← links)
- Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1 ) and receptor-5 (S1P5 ) agonist with autoimmune disease-modifying activity (Q34518822) (← links)
- Biocomparison of Three Formulations of the S1P1 Receptor Modulator Ponesimod in Healthy Subjects. (Q35807339) (← links)
- Modelling and sample size reestimation for longitudinal count data with incomplete follow up. (Q36410659) (← links)
- Effects of multiple-dose ponesimod, a selective S1P1 receptor modulator, on lymphocyte subsets in healthy humans (Q37551687) (← links)
- Sphingosine 1-Phosphate Receptor Modulators and Drug Discovery (Q37551932) (← links)
- S1P signaling: new therapies and opportunities (Q38314882) (← links)
- Emerging oral drugs for psoriasis (Q38341175) (← links)
- Oral drugs in multiple sclerosis therapy: an overview and a critical appraisal (Q38534132) (← links)
- Fingolimod hydrochloride for the treatment of relapsing remitting multiple sclerosis (Q38606914) (← links)
- Agreement of MSmetrix with established methods for measuring cross-sectional and longitudinal brain atrophy (Q38631344) (← links)
- The Latest Innovations in the Drug Pipeline for Multiple Sclerosis (Q38678739) (← links)
- The Use of Oral Disease-Modifying Therapies in Multiple Sclerosis (Q38761495) (← links)
- Clinical pharmacology, efficacy, and safety aspects of sphingosine-1-phosphate receptor modulators. (Q38850104) (← links)
- Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway: Therapeutic Targets in Autoimmunity and Inflammation (Q38869471) (← links)
- Therapeutic Strategies and Pharmacological Tools Influencing S1P Signaling and Metabolism (Q38915115) (← links)
- Novel targets in the treatment of chronic graft-versus-host disease (Q39023963) (← links)
- Ponesimod--a future oral therapy for psoriasis? (Q39144447) (← links)
- Sphingosine 1-Phosphate Receptor 1 Signaling in Mammalian Cells (Q39152899) (← links)
- Targeting sphingosine-1-phosphate signaling for cancer therapy (Q39379449) (← links)
- Impact of Demographics, Organ Impairment, Disease, Formulation, and Food on the Pharmacokinetics of the Selective S1P1 Receptor Modulator Ponesimod Based on 13 Clinical Studies (Q39379962) (← links)
- Benefit-Risk Profile of Sphingosine-1-Phosphate Receptor Modulators in Relapsing and Secondary Progressive Multiple Sclerosis (Q40047199) (← links)
- Modeling the Effect of the Selective S1P1 Receptor Modulator Ponesimod on Subsets of Blood Lymphocytes. (Q40405233) (← links)
- Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial (Q40569176) (← links)
- Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial (Q40790707) (← links)
- Differential effects of ponesimod, a selective S1P1 receptor modulator, on blood-circulating human T cell subpopulations (Q41676406) (← links)
- Cardiac Safety of Ozanimod, a Novel Sphingosine-1-Phosphate Receptor Modulator: Results of a Thorough QT/QTc Study. (Q46025818) (← links)
- Spotlight on siponimod and its potential in the treatment of secondary progressive multiple sclerosis: the evidence to date (Q47155392) (← links)
- Pharmacokinetics, Pharmacodynamics, Tolerability, and Food Effect of Cenerimod, a Selective S1P₁ Receptor Modulator in Healthy Subjects. (Q47430919) (← links)
- Modeling Tolerance Development for the Effect on Heart Rate of the Selective S1P1 Receptor Modulator Ponesimod (Q47980601) (← links)
- Absolute Bioavailability of Ponesimod, a Selective S1P1 Receptor Modulator, in Healthy Male Subjects (Q48237090) (← links)
- Effect of Hepatic or Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Ponesimod, a Selective S1P1 Receptor Modulator (Q50781520) (← links)
- Three different up-titration regimens of ponesimod, an S1P1 receptor modulator, in healthy subjects (Q51062516) (← links)
- Mitigation of Initial Cardiodynamic Effects of the S1P1 Receptor Modulator Ponesimod Using a Novel Up-Titration Regimen. (Q51552299) (← links)
- Oral Therapies for Multiple Sclerosis (Q51745062) (← links)
- Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study (Q57040164) (← links)
- An update on sphingosine-1-phosphate receptor 1 modulators (Q58604755) (← links)
- Promising Multiple Sclerosis Agents In Late-Stage Development (Q60923135) (← links)
- Emerging small-molecule treatments for multiple sclerosis: focus on B cells (Q64076437) (← links)
- Therapeutic Potential of Ponesimod Alone and in Combination with Dimethyl Fumarate in Experimental Models of Multiple Sclerosis. (Q64885022) (← links)
- Ozanimod: a better or just another S1P receptor modulator? (Q87297001) (← links)
- Advances in oral immunomodulating therapies in relapsing multiple sclerosis (Q89720958) (← links)
- Progressive multiple sclerosis: latest therapeutic developments and future directions (Q90618604) (← links)
- Sphingosine-1-phosphate signalling drives an angiogenic transcriptional programme in diffuse large B cell lymphoma (Q92091732) (← links)
- ASP1126, a Novel Sphingosine-1-Phosphate-Selective Agonist With a Favorable Safety Profile, Prolongs Allograft Survival in Rats and Nonhuman Primates in Combination With Tacrolimus With a Broad Safety Margin for Bradycardia (Q92531843) (← links)